Skip to content
  • Home
  • Pipeline
  • Biology
  • Team
  • Investors
  • News & Events
CONTACT US

Tag: scleroderma

APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis

Presentation at IPF Summit Elucidates APT-101 Mechanism of Action

International Workshop of Scleroderma Research

Preclinical results support the potential of APT-101 as a therapeutic for ILD, including those cases associated with SSc-ILD

APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis

APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research

Contact us to get more information about the company and the compelling nonclinical studies results that supports moving the program into human clinical trials.
CONTACT US
QUICK CONTACT
  • APIE Therapeutics
  • P.O. Box 13169 2 Davis Dr. RTP, NC 27709
  • +1 (919) 594-1985
  • info@apie-therapeutics.com
USEFUL LINKS
  • Home
  • Pipeline
  • Biology
  • Team
  • Investors
  • News

© 2020 APIE Therapeutics. All rights reserved

  • Privacy Policy
  • Term of Service
  • Legal info